For how we live.
A cohort with serial MRI and autopsy data found earlier menopause tracked faster cognitive decline and white matter damage. The per-year coefficients are very small.
A ten-person phase 1 study measured whether oral rapamycin reaches the central nervous system in early Alzheimer's. It did not — and several disease biomarkers rose over eight weeks.
The approved tests are for patients already showing cognitive decline. Used on the worried well, a positive result mostly signals a risk that may never become disease — and no treatment follows from it.
University of Florida researchers identify excess glycan production as a driver of Alzheimer's pathology, and find oral glucosamine worsened cognition in mice and tracked with faster decline.
Researchers profiled nearly 356,000 nuclei from post-mortem hippocampi across five groups. Chromatin accessibility in neurogenic cells was already altered in people with preclinical Alzheimer's pathology.
Three February papers push plasma p-tau217 past detection: clock models estimating years to symptom onset, four assays compared head to head, and a real-world audit of what the result changes.
In 85 people with mild cognitive impairment, transient beta-band events recorded at rest differed years before diagnosis. The sample is small and the finding has not been replicated.
The biomarker effect reported at CTAD is large and sustained over two years. The sample is seven, the design is open dose-escalation, and imaging was available for three.
A small longitudinal study found reduced spindle activity over the temporal lobes in early Alzheimer's — and that lower temporal spindle density tracked with faster decline over up to seven years.
At a Mayo Clinic cohort of 252 patients, 40% of amyloid-negative people tested positive. The manufacturer says it has found a manufacturing problem and put the product on hold.
Bristol Myers Squibb found 'irregularities' in how a small number of ADEPT-2 sites executed the study, excluded their patients, and is enrolling more. Alzheimer's-related psychosis still has no approved treatment.
Semaglutide moved Alzheimer's biomarkers without moving the clinic. A separate liraglutide trial missed its primary endpoint on brain metabolism. Together they close a decade-old hypothesis — or at least narrow it.
Sequencing hundreds of single neurons from 15 donors with CTE and 4 with repetitive head impacts but no CTE, researchers found the genomic damage tracked the disease, not the exposure.